|
시장보고서
상품코드
1890963
지중해빈혈 시장 : 유형별, 치료별, 최종사용자별, 투여 경로별, 유통 채널별, 연령층별, 지역별Thalassemia Market, By Type, By Treatment Type, By End User, By Route of Administration, By Distribution Channel, By Age Group, By Geography |
||||||
지중해빈혈 시장은 2025년에 9억 8,950만 달러로 추정되며, 2032년까지 16억 8,480만 달러에 달할 것으로 예측됩니다. 2025-2032년까지 CAGR 7.9%로 성장할 것으로 전망됩니다.
| 보고서 커버 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2024년 | 2025년 시장 규모: | 9억 8,950만 달러 |
| 과거 데이터 대상 기간: | 2020-2024년 | 예측 기간: | 2025-2032년 |
| 예측 기간 2025-2032년: | 7.90% | 2032년의 예측 가치: | 16억 8,480만 달러 |
지중해빈혈은 헤모글로빈 합성 결함을 특징으로 하는 유전성 혈액 질환군으로, 전 세계 수백만 명의 환자에게 영향을 미치는 심각한 세계 건강 문제입니다. 이 유전성 질환은 주로 지중해 지역, 동남아시아, 아프리카, 중동에서 많이 발견되며, 알파 또는 베타 글로빈 사슬의 생산이 감소 또는 소실되어 만성 빈혈, 장기 장애, 큰 의료 부담을 유발합니다.
세계 지중해빈혈 시장은 진단 도구, 치료 중재, 수혈 서비스, 철분 킬레이트 요법, 유전자 치료 등 지중해빈혈 환자의 복잡한 의료적 요구를 충족시키는 종합적인 생태계를 포괄합니다. 유전자 스크리닝에 대한 인식의 증가, 태아 진단의 발전, CRISPR-Cas9와 같은 유전자 편집 기술의 혁신적인 발전으로 인해 최근 몇 년 동안 이 시장은 전례 없는 변화를 겪었습니다. 환자 수 증가와 더불어 개발도상국의 의료비 지출 확대, 연구개발에 대한 막대한 투자가 시장 확대를 지속적으로 견인하고 있습니다. 또한, 신약개발에 있어서 인공지능의 통합, 맞춤형 의료 접근법, 제약기업과 연구기관과의 협력관계는 치료 패러다임을 재구성하고, 세계 지중해빈혈 시장 상황에 새로운 수익 기회를 창출하고 있습니다.
시장 역학
세계 지중해빈혈 시장의 성장은 몇 가지 강력한 촉진요인에 의해 뒷받침되고 있습니다. 특히 근친혼과 유전적 소인이 발병률 상승에 기여하는 유행지역에서 지중해빈혈 질환의 전 세계 유병률 증가를 들 수 있습니다. 유전자 치료 분야의 기술적 진보, 예를 들어 진테그로(베티베글루젠 오토템셀) 및 기타 첨단 치료법의 개발은 증상 관리가 아닌 질병의 근본 원인을 다루는 혁신적인 치료 접근법을 구현하고 있습니다. 신흥국들의 헬스케어 인프라 확충, 희귀질환 관리를 위한 정부 정책 강화, 희귀질환 치료제 개발에 대한 막대한 자금 투입이 맞물리면서 시장 성장을 지속적으로 견인하고 있습니다. 유전 상담, 산전 검사 프로그램, 조기 진단에 대한 인식이 높아짐에 따라 즉각적인 개입이 필요한 환자를 찾아내어 시장 확대에 크게 기여하고 있습니다.
그러나 유전자 치료와 같은 첨단 치료법은 환자 1인당 280만 달러가 넘는 고가의 비용으로 인해 중저소득국가의 환자들에게 접근 장벽으로 작용하는 등 시장 진입에 큰 제약이 존재합니다. 혁신적인 치료법에 대한 복잡한 규제 승인 절차, 제한된 전문 의료 시설, 훈련된 혈액 전문의의 부족도 심각한 문제입니다. 특정 지역에서의 유전자 검사 및 산전 검사에 대한 문화적, 종교적 장벽도 시장 침투를 더욱 가로막고 있습니다. 이러한 도전과제가 있는 반면, 제약 대기업과 바이오 기업 간의 연구 협력 증가, CRISPR 기반 유전자 편집 기술의 적용 확대, 벤처 캐피탈의 희귀질환 치료에 대한 관심 증가 등을 통해 큰 기회가 창출되고 있습니다. 보다 저렴한 치료 옵션의 개발, 희귀 질환에 대한 의료 보험 적용 범위 확대, 개발도상국에서의 전문 지중해빈혈 센터 설립은 시장 이해관계자들에게 유망한 성장 전망을 보여주고 있습니다.
본 조사의 주요 특징
- 본 보고서는 2024년을 기준 연도로 하여 세계 지중해빈혈증 시장에 대한 상세한 분석을 제공하며, 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 조사하여 제시합니다.
- 각 부문의 잠재적 수익기회를 확인하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 촉진요인, 저해요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 시장 진입업체들이 채택하고 있는 경쟁 전략에 대한 중요한 정보도 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 지중해빈혈 시장의 주요 기업 프로파일을 제시합니다. 회사 개요,제품 포트폴리오,주요 하이라이트,재무 실적,전략
- 이 보고서는 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 지중해빈혈 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 지중해빈혈증 시장 분석에 사용된 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 범위
- 보고서 개요
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porters 분석
- 인수합병 동향
- 산업 동향
제4장 세계의 지중해빈혈 시장 : 유형별, 2020-2032년
- 알파 지중해빈혈
- 베타 지중해빈혈
- 델타 지중해빈혈
- 복합형 지중해빈혈(혼합형)
제5장 세계의 지중해빈혈 시장 : 치료 유형별, 2020-2032년
- 수혈 요법
- 철킬레이트 요법
- 줄기세포 이식
- 유전자 치료
- 약제 요법(예 : 하이드록시요소, 루스파터셉트)
- 기타(지지요법)
제6장 세계의 지중해빈혈 시장 : 최종사용자별, 2020-2032년
- 병원과 클리닉
- 진단 실험실
- 연구기관과 학술기관
- 전문 치료 센터
제7장 세계의 지중해빈혈 시장 : 투여 경로별, 2020-2032년
- 경구
- 비경구
제8장 세계의 지중해빈혈 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제9장 세계의 지중해빈혈 시장 : 연령층별, 2020-2032년
- 성인
- 소아
- 노인
제10장 세계의 지중해빈혈 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제11장 경쟁 구도
- bluebird bio Inc.
- Bristol Myers Squibb Company
- Novartis AG
- Chiesi Farmaceutici S.p.A.
- Vertex Pharmaceuticals Incorporated
- CRISPR Therapeutics AG
- Acceleron Pharma Inc.
- Ionis Pharmaceuticals Inc.
- Natco Pharma
- Silence Therapeutics plc
- Apotex Inc.
- Cipla Limited
- Sun Pharmaceutical Industries Ltd
- Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd
제12장 애널리스트의 추천사항
- 기회
- Coherent Opportunity Map
제13장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Thalassemia Market is estimated to be valued at USD 989.5 Mn in 2025 and is expected to reach USD 1,684.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 989.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.90% | 2032 Value Projection: | USD 1,684.8 Mn |
Thalassemia represents a significant global health challenge, constituting a group of inherited blood disorders characterized by defective hemoglobin synthesis that affects millions of individuals worldwide. This genetic condition, predominantly prevalent in Mediterranean regions, Southeast Asia, Africa, and the Middle East, results in reduced or absent production of alpha or beta globin chains, leading to chronic anemia, organ damage, and substantial healthcare burden.
The global thalassemia market encompasses a comprehensive ecosystem of diagnostic tools, therapeutic interventions, blood transfusion services, iron chelation therapies, and emerging gene therapies that collectively address the complex medical needs of thalassemia patients. With increasing awareness about genetic screening, advances in prenatal diagnosis, and revolutionary developments in gene editing technologies like CRISPR-Cas9, the market has witnessed unprecedented transformation in recent years. The growing patient population, coupled with rising healthcare expenditure in developing nations and significant investments in research and development activities, continues to drive market expansion. Additionally, the integration of artificial intelligence in drug discovery, personalized medicine approaches, and collaborative efforts between pharmaceutical companies and research institutions are reshaping treatment paradigms and creating new revenue opportunities across the global thalassemia market landscape.
Market Dynamics
The global thalassemia market is propelled by several compelling drivers, including the increasing prevalence of thalassemia disorders worldwide, particularly in endemic regions where consanguineous marriages and genetic predisposition contribute to higher incidence rates. Technological advancements in gene therapy, such as the development of Zynteglo (betibeglogene autotemcel) and other cutting-edge treatments, represent revolutionary therapeutic approaches that address the root cause of the disease rather than managing symptoms. Growing healthcare infrastructure in emerging economies, coupled with increased government initiatives for rare disease management and substantial funding for orphan drug development, continues to fuel market growth. Rising awareness about genetic counseling, prenatal screening programs, and early diagnosis significantly contribute to market expansion by identifying patients who require immediate intervention.
However, the market faces considerable restraints, including the extremely high cost of advanced therapies like gene therapy, which can exceed US$ 2.8 million per patient, creating accessibility barriers for patients in low and middle-income countries. Complex regulatory approval processes for innovative treatments, limited availability of specialized healthcare facilities, and shortage of trained hematologists pose significant challenges. Cultural and religious barriers in certain regions regarding genetic testing and prenatal screening further impede market penetration. Despite these challenges, substantial opportunities emerge through increasing research collaborations between pharmaceutical giants and biotechnology companies, expanding applications of CRISPR-based gene editing technologies, and growing interest from venture capital firms in rare disease therapeutics. The development of more affordable treatment alternatives, expansion of healthcare insurance coverage for rare diseases, and establishment of specialized thalassemia centers in developing countries present lucrative growth prospects for market stakeholders.
Key Features of the Study
- This report provides in-depth analysis of the global thalassemia market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global thalassemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include bluebird bio Inc., Bristol Myers Squibb Company, Novartis AG, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Acceleron Pharma Inc., Ionis Pharmaceuticals Inc., Natco Pharma, Silence Therapeutics plc, Apotex Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global thalassemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thalassemia market
Market Segmentation
- Type Insights (Revenue, USD Mn, 2020 - 2032)
- Alpha Thalassemia
- Beta Thalassemia
- Delta Thalassemia
- Combination Thalassemia (Mixed Type)
- Treatment Type Insights (Revenue, USD Mn, 2020 - 2032)
- Blood Transfusion Therapy
- Iron Chelation Therapy
- Stem Cell Transplantation
- Gene Therapy
- Pharmacotherapy (e.g., Hydroxyurea, Luspatercept)
- Others (Supportive Care)
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals and Clinics
- Diagnostic Laboratories
- Research and Academic Institutions
- Specialty Treatment Centers
- Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Parenteral
- Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- bluebird bio Inc.
- Bristol Myers Squibb Company
- Novartis AG
- Chiesi Farmaceutici S.p.A.
- Vertex Pharmaceuticals Incorporated
- CRISPR Therapeutics AG
- Acceleron Pharma Inc.
- Ionis Pharmaceuticals Inc.
- Natco Pharma
- Silence Therapeutics plc
- Apotex Inc.
- Cipla Limited
- Sun Pharmaceutical Industries Ltd
- Reddy's Laboratories Ltd
- Teva Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Thalassemia Market, By Type
- Global Thalassemia Market, By Treatment Type
- Global Thalassemia Market, By End User
- Global Thalassemia Market, By Route of Administration
- Global Thalassemia Market, By Distribution Channel
- Global Thalassemia Market, By Age Group
- Global Thalassemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Thalassemia Market, By Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Alpha Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Delta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Combination Thalassemia (Mixed Type)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Thalassemia Market, By Treatment Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Blood Transfusion Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Iron Chelation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Pharmacotherapy (e.g., Hydroxyurea, Luspatercept)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Supportive Care)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Thalassemia Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Research and Academic Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Specialty Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Thalassemia Market, By Route of Administration, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Thalassemia Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Thalassemia Market, By Age Group, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Thalassemia Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- bluebird bio Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiesi Farmaceutici S.p.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CRISPR Therapeutics AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acceleron Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Natco Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
